Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2015 Jul 23;14(10):2249–2259. doi: 10.1158/1535-7163.MCT-15-0429

Figure 4. Potentiation of effects of PKC412 or AC220 by CGM097 against mutant FLT3-positive AML cells cultured in the absence and the presence of cytoprotective SCM.

Figure 4

Approximately 2-day treatment of FLT3-ITD-expressing MOLM14 cells with PKC412, CGM097, or a combination of both in the presence of (A) RPMI+10% FBS, (B) HS-5 SCM (90%), (C) HS27a SCM (90%). (D) Direct comparison of effects of PKC412 against MOLM14 cells cultured in the presence of RPMI+10% FBS, HS-5 SCM (90%), or HS27a SCM (90%). (E-F) Investigation of PUMA and Mcl-1 expression in drug-treated MOLM14 cells following 24 hours of treatment.